J E Robinson1, E W Fish, M C Krouse, A Thorsell, M Heilig, C J Malanga. 1. Department of Neurology and Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill, 170 Manning Dr., CB 7025, Chapel Hill, NC 27599-7025, USA.
Abstract
RATIONALE: The abuse potential of opioids may be due to their reinforcing and rewarding effects, which may be attenuated by neurokinin-1 receptor (NK1R) antagonists. OBJECTIVE: This study was conducted to measure the effects of opioid and NK1R blockade on the potentiation of brain stimulation reward (BSR) by morphine using the intracranial self-stimulation method. METHODS: Adult male C57BL/6J mice (n = 15) were implanted with unipolar stimulating electrodes in the lateral hypothalamus and trained to respond for varying frequencies of rewarding electrical stimulation. The BSR threshold (θ(0)) and maximum response rate (MAX) were determined before and after intraperitoneal administration of saline, morphine (1.0-17.0 mg/kg), or the NK1R antagonists L-733,060 (1.0-17.0 mg/kg) and L-703,606 (1.0-17.0 mg/kg). In morphine antagonism experiments, naltrexone (0.1-1.0 mg/kg) or 10.0 mg/kg L-733,060 or L-703,606 was administered 15 min before morphine (1.0-10.0 mg/kg) or saline. RESULTS: Morphine dose-dependently decreased θ(0) (maximum effect = 62% of baseline) and altered MAX when compared to saline. L-703,606 and L-733,060 altered θ(0); 10.0 mg/kg L-733,060 and L-703,606, which did not affect θ(0) or MAX, attenuated the effects of 3.0 and 10.0 mg/kg morphine, and 1.0 and 0.3 mg/kg naltrexone blocked the effects of 10.0 mg/kg morphine. Naltrexone given before saline did not affect θ(0) or MAX. CONCLUSIONS: The decrease in θ(0) by morphine reflects its rewarding effects, which were attenuated by NK1R and opioid receptor blockade. These results demonstrate the importance of substance P signaling during limbic reward system activation by opioids.
RATIONALE: The abuse potential of opioids may be due to their reinforcing and rewarding effects, which may be attenuated by neurokinin-1 receptor (NK1R) antagonists. OBJECTIVE: This study was conducted to measure the effects of opioid and NK1R blockade on the potentiation of brain stimulation reward (BSR) by morphine using the intracranial self-stimulation method. METHODS: Adult male C57BL/6J mice (n = 15) were implanted with unipolar stimulating electrodes in the lateral hypothalamus and trained to respond for varying frequencies of rewarding electrical stimulation. The BSR threshold (θ(0)) and maximum response rate (MAX) were determined before and after intraperitoneal administration of saline, morphine (1.0-17.0 mg/kg), or the NK1R antagonists L-733,060 (1.0-17.0 mg/kg) and L-703,606 (1.0-17.0 mg/kg). In morphine antagonism experiments, naltrexone (0.1-1.0 mg/kg) or 10.0 mg/kg L-733,060 or L-703,606 was administered 15 min before morphine (1.0-10.0 mg/kg) or saline. RESULTS:Morphine dose-dependently decreased θ(0) (maximum effect = 62% of baseline) and altered MAX when compared to saline. L-703,606 and L-733,060 altered θ(0); 10.0 mg/kg L-733,060 and L-703,606, which did not affect θ(0) or MAX, attenuated the effects of 3.0 and 10.0 mg/kg morphine, and 1.0 and 0.3 mg/kg naltrexone blocked the effects of 10.0 mg/kg morphine. Naltrexone given before saline did not affect θ(0) or MAX. CONCLUSIONS: The decrease in θ(0) by morphine reflects its rewarding effects, which were attenuated by NK1R and opioid receptor blockade. These results demonstrate the importance of substance P signaling during limbic reward system activation by opioids.
Authors: J Elliott Robinson; Abigail E Agoglia; Eric W Fish; Michael C Krouse; C J Malanga Journal: Behav Brain Res Date: 2012-06-21 Impact factor: 3.332
Authors: Eyal Vardy; J Elliott Robinson; Chia Li; Reid H J Olsen; Jeffrey F DiBerto; Patrick M Giguere; Flori M Sassano; Xi-Ping Huang; Hu Zhu; Daniel J Urban; Kate L White; Joseph E Rittiner; Nicole A Crowley; Kristen E Pleil; Christopher M Mazzone; Philip D Mosier; Juan Song; Thomas L Kash; C J Malanga; Michael J Krashes; Bryan L Roth Journal: Neuron Date: 2015-04-30 Impact factor: 17.173
Authors: Jesse R Schank; Courtney E King; Hui Sun; Kejun Cheng; Kenner C Rice; Markus Heilig; David Weinshenker; Jason P Schroeder Journal: Neuropsychopharmacology Date: 2013-10-31 Impact factor: 7.853
Authors: Eric W Fish; J Elliott Robinson; Michael C Krouse; Clyde W Hodge; Cheryl Reed; Tamara J Phillips; C J Malanga Journal: Psychopharmacology (Berl) Date: 2011-10-07 Impact factor: 4.530
Authors: A Leslie Morrow; C J Malanga; Eric W Fish; Buddy J Whitman; Jeff F DiBerto; J Elliott Robinson Journal: Psychopharmacology (Berl) Date: 2014-05-09 Impact factor: 4.530